Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical natural killer cell therapy
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational adoptive cellular immunotherapy, developed by the M.D. Anderson Cancer Center, involves the infusion of natural killer (NK) cells derived from haploidentical (partially matched) related donors. The therapy is specifically being evaluated for patients with chronic myeloid leukemia (CML) who have failed to achieve cytogenetic remission after treatment with at least two tyrosine kinase inhibitors (TKIs), or those who have progressed to the accelerated or blast phases. The treatment protocol typically involves a lymphodepleting conditioning regimen (such as fludarabine and busulfan) followed by the infusion of donor NK cells and a subsequent allogeneic stem cell transplant. The donor NK cells are intended to provide a graft-versus-leukemia (GVL) effect by recognizing and eliminating residual malignant cells, often supported by the administration of Interleukin-2 (IL-2) to enhance cell survival and expansion.
- Other names
- NK cell infusionhaploidentical NK cellsdonor-derived natural killer cellsNatural Killer Cells-M.D. Anderson Cancer Center-chronic myeloid leukemia
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on haploidentical natural killer cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical natural killer cell therapy.